AZN vs MGNX

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

MGNX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration across all financial health dimensions. While the company shows explosive revenue growth (113% YoY) and maintains a strong liquidity position (Current Ratio 5.10), it suffers from negative gross margins and a consistent track record of missing earnings estimates. The recent 1-year price surge appears decoupled from fundamental value, as the company remains deeply unprofitable with a catastrophic ROE of -86.94%.